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Abstract 
Background. The pathophysiologic mechanisms leading to aortic stenosis (AS) are characterized 
by early atherosclerosis and inflammation. Epicardial adipose tissue (EAT) represents a source of 
several pro-atherogenic inflammatory mediators involved in coronary atherogenesis. EAT thickness 
and inflammatory profile are  increased in patients with coronary artery disease (CAD). Since the 
well recognized similarities between AS and CAD pathogenesis, we aimed to evaluate whether 
anatomic characteristics and pro-inflammatory profile of EAT are also modified in patients with 
severe isolated AS.  
Methods and Results. We measured EAT thickness by echocardiography in 95 patients with 
isolated AS and 44 controls matched for age, gender and body mass index (BMI). In patients 
referred to aortic valve replacement, plasma, EAT and subcutaneous adipose tissue (SCAT) were 
collected and analyzed by human cytokine 27 multiplex immunoassay for the assessment of 
systemic and local inflammatory status. EAT thickness was significantly increased in patients with 
AS compared to controls. Overall, EAT showed a markedly increased inflammatory profile respect 
to SCAT. There was a significant relationship between EAT thickness and levels of EAT secreted 
inflammatory mediators.  
Conclusions.  Our results provide the first demonstration of EAT increased thickness and 
inflammatory status in patients with severe AS. Overall, these data raise the hypothesis of a 
potential role of EAT in AS pathogenesis. 
Introduction 
Aortic stenosis (AS) is the most prevalent form of valvular heart disease and becomes more 
prevalent with increasing age (1). It is widely recognized that aortic valve (AV) leaflets thickening 
and calcification are regulated by active processes which include chronic inflammation, lipoprotein 
deposition and activation of specific osteogenic and apoptotic signaling pathways (2). These 
phenomena lead to activation and differentiation of valvular interstitial cells into myofibroblasts and 
osteoblast-like cells, with consequent bone deposition (2–4).   
Inflammation plays a crucial role in AV calcification both in early and advanced stages (5, 6). 
Similarly to the early stages of vascular atherosclerosis, the disruption of the endothelial continuity 
allows the infiltration of inflammatory cells and, importantly, of circulating lipids (7) that undergo 
oxidative modifications (8) and stimulate inflammatory activity and valve mineralization. Further, 
AS and coronary artery disease (CAD) share common risk factors (9-11), early pathogenesis (6), 
and clinical coexistence (12) with an high percentage (40% to 75%) of patients with severe AS and 
concomitant CAD. Thus, it is reasonable to hypothesize that the pathogenesis and progression of 
AS and CAD might be induced by similar stimuli, largely represented by the inflammatory activity 
intrinsic to the atherogenesis process. 
Epicardial adipose tissue (EAT) is the visceral fat depot of the heart  and it shares the same 
microcirculation with the myocardium. EAT has been shown to be predictive of cardiovascular 
events independently of conventional risk factors and body mass index (BMI) (13). The 
mechanisms by which EAT exerts its role in the atherogenesis seem to be related to the production 
and secretion of several inflammatory mediators (14-16). In particular, Mazurek et al. demonstrated 
in CAD patients that EAT secretes significant higher levels of cytokines and chemokines than 
subcutaneous adipose tissue (SCAT) irrespective of clinical variables and plasma concentrations of 
circulating biomarkers (14). EAT seems to be closely related to atherosclerosis in a mass-dependent 
way, and its volume is associated with the presence and severity of CAD (17) and coronary artery 
calcification (18).  
In this context, we sought to investigate whether EAT could also contribute to the inflammatory 
burden of AS. To this aim, we analyzed anatomic characteristics and secretory profile of EAT 
obtained from patients with isolated, calcific AS.   
 
Methods 
Study Population 
In the present study, we enrolled 95 patients with severe, isolated, calcific AS. All subjects were 
referred to cardiac surgery for AV replacement and underwent a complete clinical and 
echocardiographic evaluation, and coronary angiography prior to intervention. Demographic and 
clinical characteristics of the study population are summarized in Table 1. Exclusion criteria were 
as follows: 1) presence of significant CAD at coronary angiography; 2) poor acoustic quality of 
parasternal view at echocardiography with inability to adequately visualize EAT; 3) presence of 
pathologic conditions associated with increased echocardiographic EAT thickness (metabolic 
syndrome, atrial fibrillation and history of CAD) (19-21); 4) chronic inflammatory diseases which 
could affect EAT thickness and/or systemic and local inflammatory profiles. The study protocol 
conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori 
approval by our institution's human research committee. All patients provided written informed 
consent before their inclusion into the study.  
Echocardiographic measurements 
Echocardiograms were performed by a VIVID E9 (GE healthcare) machine according to standard 
technique. Echocardiographic images were recorded through an EchoPAC Clinical Workstation 
Software (GE Healthcare).  
Measurements of EAT thickness were obtained from a parasternal long axis view. EAT thickness 
was measured perpendicularly to the free wall of right ventricle, at end systole, in 3 cardiac cycles 
as previously described by Iacobellis et al (22). Echocardiographic parameters are reported in Table 
1. Measurements of EAT thickness were performed offline by two independent echocardiographers. 
The average value from three cardiac cycles was used for the statistical analysis. The intra-observer 
and inter-observer correlation coefficients were tested.  
EAT thickness was also measured in a control group of 44 healthy subjects, matched for age, 
gender and BMI screened  by echocardiographic and clinical database of our Institution. In these 
control subjects, we excluded the presence of cardiovascular disease, cardiovascular risk factors, 
renal diseases, systemic inflammatory diseases or any cardiovascular drug therapy. 
Tissues Collection  
On the morning of surgery, a peripheral venous blood sample was drawn from all AS patients into 
EDTA tubes, and then centrifuged within 20 minutes at 1500g for 10 minutes at 4°C. Plasma was 
stored in aliquots at -80°C for all ELISA assays.  
From a subgroup of 10 patients, we obtained EAT and SCAT samples during cardiac surgery for 
AV replacement. Adipose tissue biopsy samples (average 0.1 to 0.5 g)  were obtained before the 
initiation of cardiopulmonary bypass. EAT biopsies were taken near the proximal right coronary 
artery, while SCAT samples were obtained from the chest. Conditioned media from EAT and 
SCAT biopsies were isolated as described by Mazurek et al (14). Briefly, the tissue was weighted, 
cut into small pieces, and transferred into a 12-well plate. According to tissue weight, serum-free 
DMEM (1 mL medium/0.1 g tissue) was added to the well and incubated at 37°C in a CO2 
incubator. After 24h, medium was collected and centrifuged at 14,000 g to remove debris and 
analyzed for cytokines and growth factors content, as described below. 
Cytokine and growth factor assay  
Plasma and conditioned media from EAT and SCAT were screened for the concentration of 
Interleukin (IL)-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-
17, basic Fibroblast Growth Factor (FGF), Eotaxin, Granulocyte-Colony Stimulating Factor (G-
CSF), Granulocyte–Macrophage Colony Stimulating Factor (GM-CSF), Interferon (IFN)-γ, 
Interferon gamma-Induced Protein (IP)-10, Monocyte Chemoattractant Protein  (MCP)-1, 
Macrophage Inflammatory Protein 1-alpha/beta (MIP-1α, MIP-1β), Platelet-Derived Growth Factor 
(PDGF), Regulated on Activation Normal T-cell Expressed and Secreted RANTES, Tumor 
Necrosis Factor (TNF)-α, and Vascular Endothelial Growth Factor (VEGF), using the Bio-Plex 
multiplex Human Cytokine and Growth factor kits (Bio-Rad) according to the manufacturer’s 
protocol. 
Statistical Analysis 
Continuous variables are presented as mean± standard deviation (SD) and compared by the use of 
Student t test (normally distributed) or as median ± interquartile range value and compared by the 
use of Mann-Whitney U test (not normally distributed), as appropriate. Normality of data 
distribution was evaluated using the Kolmogorov-Smirnov test. Not normally distributed 
continuous variables were natural log transformed. Categorical variables are expressed as 
proportion and compared by use of χ2 test. Associations between EAT thickness and EAT 
inflammatory profile was determined with the Pearson correlation coefficient.  
All data were collected in an Excel database and analyzed by SPSS version 19.0 (SPSS, Inc., 
Chicago, Illinois). Statistical significance was accepted at p <0.05. 
 
Results 
Patient Characteristics 
Table 1 illustrates demographic and clinical characteristics of the study population. The mean age 
was 72.5 years and 60% of patients  were females. As regard to common atherosclerotic risk 
factors, 42% of patients showed dyslipidemia, 29% were diabetics, 66% were hypertensives and 
26% were smokers. 8.4 % of patients had glomerular filtration rate (GFR) < 60% ml/min. Use of 
aspirin and statins was reported in 40% and 37.9% of patients respectively. Almost 50% of patients 
assumed beta-blockers and ACE-inhibitors/sartans.  
At echocardiography, all patients showed echocardiographic findings of severe aortic stenosis (AV 
area 0.8±0.2 cm
2
 with a mean gradient of 44.2±19.6 mmHg) and left ventricular (LV) diastolic 
dysfunction. Mean LV ejection fraction was 64%, thus indicating a globally preserved LV systolic 
function.  Patients of control group had a mean age of 70.41±10.6 years and a BMI of 26.4±2.4. The 
percentage of females was 54.5% (n. 24 subjects). 
EAT thickness 
EAT thickness was markedly increased in patients with AS respect to control subjects matched for 
age, gender and BMI (9.85±2.78 vs 4.91±1.27 mm; p<0.0001) (Figure 1). Intra and inter-observer 
reproducibility for echocardiographic EAT thickness assessment was excellent (0.962 and 0.951, 
respectively).  
Demographic and clinical variables were also evaluated after study population stratification above 
and below EAT thickness median value (Table 2). There were no differences between the two 
groups for age, BMI, GFR and atherosclerotic risk factors. Interestingly, as regard to cardiovascular 
therapy, only statin use was significantly higher in patients below the EAT thickness median value. 
Although both subgroups showed preserved LV systolic function, patients below the EAT thickness 
median value presented higher LV ejection fraction. 
  
Inflammatory secretory profile of Epicardial Adipose Tissue 
 
EAT secretome was characterized by higher levels of inflammatoty mediators than those observed 
in SCAT (Figure 2). In fact, of 27 factors analyzed we found that levels of IL-1β, IL-1ra, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-15, IL-17, eotaxin, G-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, 
MIP-1β, TNF-α, VEGF, were significantly increased in EAT secretome compared to SCAT. 
Noteworthy, IL-1β, IL-1ra, IL-4, IL-10, IL-12, eotaxin, IFN-γ, TNF-α,VEGF and PDGF showed 
more than two fold increase, and IL-6, IL-8, G-CSF, IP-10, MIP-1α and MIP-1β  more than fivefold 
increase in EAT compared to SCAT secretome (Table 3). Only IL-13 levels were higher in SCAT 
than in EAT. Interestingly, after patients stratification above and below EAT thickness median 
value, no differences were found between the two groups  in plasma inflammatory mediators levels, 
except for PDGF and VEGF. Contrarily,  in EAT secretome, 22 of 27 measured inflammatory 
mediators   levels were significantly higher in patients above the EAT thickness median value 
(Table 4). 
Since the above mentioned observation of a larger use of statins in patients below EAT thickness 
median value, we tested differences, in plasma and EAT secretome, in inflammatory mediators 
levels between patients taking and non taking statins (Table 5). In plasma, we found that only IL-6 
and MIP-1α  were significantly lower in statin users than in non users. Contrarily, in EAT 
secretome, all inflammatory mediators, except for PDGF, IL-13, G-CSF, GM-CSF, RANTES and 
VEGF,  were significantly reduced in patients on statin therapy. 
 
EAT thickness and EAT inflammatory profile 
We tested the relationship between EAT echocardiographic thickness and its inflammatory profile. 
Interestingly, we found a close direct correlation between EAT thickness and levels of secreted 
inflammatory mediators. In particular, EAT thickness significantly correlated with levels of IL-1β, 
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17, basic FGF, eotaxin, G-CSF, 
IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF and TNF-α (Table 6).  
 
Discussion 
The present study analyzed, for the first time, morphologic characteristics and inflammatory profile 
of EAT in patients with isolated AS. Major findings of the present study are: 1) patients with AS 
had an increased EAT thickness compared to controls; 2) EAT of patients with AS showed an 
increased secretion of cytokines, chemokines, and growth factors compared to SCAT; 3) there was 
a close relationship between EAT thickness and its secretion of inflammatory mediators. 
 
EAT thickness in Aortic Stenosis 
 
EAT represents the true visceral fat depot of the heart. Under normal physiologic conditions, EAT 
plays several protective functions for the heart by absorbing the excess of fatty acids, serving as a 
local energy source in conditions of increased metabolic demand, and, as brown fat, protecting the 
myocardium against hypothermia (23). The anatomic proximity to the heart, the absence of fascial 
boundaries, and the presence of a common microcirculation underlie the close interaction between 
the myocardium and its visceral fat depot (23). However, it is known that EAT may also play an 
unfavorable activity for the heart. In fact, it is a source of several pro-inflammatory and pro-
atherogenic cytokines and chemoattractant factors, which can biologically influence the 
myocardium and epicardial coronary arteries through paracrine or vasocrine actions (15, 24, 25).  It 
has been described that EAT could influence, through an exalted secretion of inflammatory 
mediators, the progression and the stability of atherosclerotic coronary plaques. Accordingly, in the 
last years, several evidence have indicated that EAT thickness represents a specific marker of 
visceral adiposity which is strongly associated with the presence and severity of atherosclerotic 
CAD (26-28). Of note, our study provides the first evidence that EAT thickness is also increased in 
patients with isolated AS. This observation further supports previous evidence indicating that CAD 
and AS share common pathogenetic mechanisms. In this regard, histologic studies have 
demonstrated that, in the early AS disease, the biological processes show similar characteristics to 
those observed in  the coronary atherosclerotic plaque (6). Furthermore, several studies have 
reported that early, pre-stenotic lesions of AV are associated with a 50% increase in the rate of 
coronary events (29, 30). 
In our study, we used echocardiography for the assessment of EAT thickness. This method has a 
good correlation with magnetic resonance EAT measurements, and with anthropometric and 
metabolic parameters (22). Further, echocardiographic measurement of EAT thickness is widely 
diffused and has an excellent reproducibility (27, 28, 31), that has been also confirmed in the 
present study.  
 
Proinflammatory Properties of Epicardial Adipose Tissue in Aortic Stenosis 
 
Several evidence address the ‘atherogenicity’ of EAT to secretion of epicardial inflammatory 
cytokines, such as TNF-α, MCP-1, IL-6, IL-1β, plasminogen activator inhibitor-1, resistin, and 
others (14,15,24).  Previous evidences have indicated that in patients with significant CAD, EAT 
secretome shows significantly higher levels of chemokines, such as MCP-1, and several 
inflammatory cytokines, as IL-1, IL-6, IL-6sR, and TNF-α compared to SCAT (14). Interestingly, it 
has been shown that local levels of these inflammatory mediators do not correlate with plasma 
concentrations of circulating cytokines and are independent of several clinical variables, such as 
obesity, and diabetes (14).  
The present study evaluated the secretory characteristics of  EAT and SCAT secretome of patients 
with AS. We found that several inflammatory and  pro-atherogenic mediators were significantly 
increased in EAT compared to SCAT. In particular, IL-6 showed more than a fivefold increase in 
EAT respect to SCAT. The involvement of IL-6 in AS has been recently described by El Husseini 
et al. (32). These authors demonstrated that high expression of IL-6 promotes the mineralization 
process of AV leaflets, which is partially reversed by IL-6 inhibition (32). Further, it has been 
described that pro-inflammatory stimulation promotes the transition of AV interstitial cells toward 
inflammatory cells resulting in a significantly increased production of  IL-6, IL-8 and MCP-1 (33-
35). As regard to IL-1β, we found a 2.5 fold increase in EAT compared to SCAT secretome. 
Histologic studies of stenotic AV leaflets have demonstrated increased levels of this potent pro-
inflammatory cytokine which promotes matrix metalloproteinase expression and cell proliferation 
in calcific AV and has been implicated in the pathogenesis of several inflammatory diseases (34, 
35). TNF-α, that showed 2.2 fold increase in EAT vs SCAT in our study, has also been detected in 
human calcified valves (36). This pleiotropic cytokine has been shown to accelerate the 
calcification of human AV interstitial cells obtained from patients with calcific AS (37).  
Overall these findings, indicating a potent pro-inflammatory activation of EAT in patients with 
isolated AS, together with the strong association observed between EAT thickness and AS, support 
the hypothesis of an involvement of cardiac visceral fat in inflammatory and atherogenic 
phenomena occurring in the AV and promoting its degeneration and calcification. To further 
strengthen this hypothesis there is the observation that EAT, but not plasma, shows a more evident 
pro-inflammatory phenotype in patients exhibiting a larger amount of cardiac visceral fat.  
 
Relationship between EAT thickness and pro-inflammatory profile 
In the present study, we have demonstrated for the first time a significant direct correlation between 
EAT thickness and levels of pro-inflammatory mediators in the EAT secretome of AS patients. 
Interestingly, the majority of measured inflammatory mediators (22 of 27) showed a highly 
significant correlation with EAT thickness assessed by echocardiography. To further support the 
link between EAT thickness and its inflammatory activity in AS, there is the observation in our 
study population that the use of statins was significantly associated with both reduced thickness and 
pro-inflammatory activity of EAT. These data are in line with the results of a recent sub-analysis of 
a large randomized clinical trial of hyperlipidemic post-menopausal women reporting that intensive 
lipid-lowering therapy induces significant EAT regression together with an attenuation of 
inflammation indexes (38). 
 
Study Limitations 
Since EAT was measured and explanted in patients with advanced AV disease, it remains unknown 
whether an increase of EAT mass together with an exalted inflammatory state of this tissue might 
be present at the initial stages of AV degeneration.  
Unfortunately, we could not obtain EAT samples from controls for comparisons. EAT from patients 
with CAD is expected to show a pro-inflammatory profile, thus it cannot reflect a normal status. 
Moreover, ethical reasons do not allow to extract EAT samples from other patients categories.  
Although our study demonstrates a strong association between the presence of AS and thickness 
and inflammatory status of EAT, the demonstration of a mechanistic role of cardiac visceral fat in 
the AS pathogenesis is still so far.  
 
Conclusions 
This study demonstrates that patients with isolated severe AS have an increased EAT thickness. 
Importantly,  increased EAT thickness also reflects an increased local inflammatory status. Further 
studies are needed in order to confirm these data and explore a potential role of EAT in the 
development of AV diseases. 
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Table 1. Demographic and clinical characteristics of the study population  
Age, years 72.52±11.22 
Gender Female, % (n)  60.0% (57) 
BMI 27.66±4.61 
Dyslipidemia, % (n) 42.1% (40) 
Diabetes, % (n) 29.5% (28) 
Hypertension, % (n) 66.3% (63) 
Smokers, % (n) 26.3% (25)  
GFR<60 ml/min 8.4% (8) 
  
Medications 
 
Aspirin, % (n) 40.0% (38) 
Statin, % (n) 37.9% (36) 
ACE-I/ARBs, % (n) 53.7% (51) 
BBs, % (n) 51.6% (49) 
  
 Echocardiographic characteristics 
LVEF, % 64.35±12.33 
E/A 3.16±15.75 
E Dec, msec 248.50±87.77 
E/e’ 15.43±5.96 
AV area, cm
2
 0.8±0.2 
Mean gradient, mmHg 44.27±19.66 
Mass, gr 180.50±45.02 
Mass / BSA, gr/m
2
 99.36±27.66 
RWT 0.44±0.10 
EAT thickness, mm 9.85±2.78 
BMI, Body Mass Index; GFR, Glomerular Filtration Rate; ACE-I, Angiotensin Converting Enzym 
inhibitors; ARB, Angiotensin Receptor Blockers; BBs, Beta-blockers; LVEF, Left Ventricular 
Ejection Fraction; AV, Aortic Valve; BSA, Body Surface Area; RWT, Relative Wall Thickness; 
EAT, Epicardial Adipose Tissue. 
 Table 2. Demographic and clinical characteristics of AS patients stratified according to  EAT thickness  
median value  
  
Pts below EAT 
median value  
(n = 46) 
Pts above EAT 
median value  
(n = 49) 
p value 
Age, mean ± SD 73.33±8.73 71.78±13.15 0.504 
Gender Female, % (n)  66.7% (30) 54% (27) 0.294 
BMI, mean ± SD 28.34±4.74 27.04±4.45 0.178 
Dyslipidemia, % (n) 48.9% (22) 36.0% (18) 0.503 
Diabetes, % (n) 35.6% (16) 24% (12) 0.482 
Hypertension, % (n) 68.9% (31) 64% (32) 0.798 
Smokers, % (n) 24.4% (11) 28% (14) 0.628 
    
Medications 
   
Aspirin, % (n) 48.9% (22) 32% (16) 0.257 
Statins, % (n) 51.1% (23) 26% (13) 0.043 
ACE-I/ARBs, % (n) 62.2% (28) 46% (23) 0.341 
BBs, % (n) 64.4% (29) 40% (20) 0.134 
    
Echocardiographic characteristics 
   
LVEF 67.36±9.89 61.78±13.66 0.03 
E/A 5.08±21.90 1.12±0.62 0.334 
E Dec 270.30±79.42 226.01±91.45 0.41 
E/e’ 16.11±6.52 14.70±5.32 0.348 
Mean gradient (mmHg) 44.41±18.74 44.15±20.69 0.951 
Mass (gr) 186.48±47.01 174.82±42.86 0.256 
Mass / BSA 99.20±30.93 99.51±24.58 0.961 
RWT 0.46±0.07 0.42±0.11 0.084 
EAT (mm) 7.58±1.51 11.90±1.92 <0.0001 
BMI, Body Mass Index; GFR, Glomerular Filtration Rate; ACE-I, Angiotensin Converting Enzym 
inhibitors; ARB, Angiotensin Receptor Blockers; BBs, Beta-blockers; LVEF, Left Ventricular 
Ejection Fraction; AV, Aortic Valve; BSA, Body Surface Area; RWT, Relative Wall Thickness; 
EAT, Epicardial Adipose Tissue. 
 
 
 
 
 
Table 3. Fold Increase in Secretion of Inflammatory Markers in Epicardial/Subcutaneous Adipose 
Tissue 
 
  
  
Fold Increase  
(95% CI) 
p value 
PDGF 2.642 (1.386 - 3.898)  .074 
IL-1β 2.508 (1.476 - 3.540) .007 
IL-1ra 3.605 (2.478 - 4.732) .005 
IL-2 1.368 (0.979 - 1.758) .036 
IL-4 2.484 (1.395 - 3.572) .009 
IL-5 1.519 (1.128 - 1.910) .011 
IL-6 6.191 (0.657 - 11.724) .005 
IL-7 1.083 (0.811 - 1.354) .838 
IL-8 11.065 (-0.321 - 22.451) .012 
IL-9 1.771 (1.136 - 2.406) .013 
IL-10 2.480 (1.602 - 3.357) .007 
IL-12 2.541 (1.738 - 3.344) .007 
IL-13 0.363 (0.190 - 0.537) .005 
IL-15 1.457 (1.092 - 1.822) .007 
IL-17 1.909 (1.669 - 2.149) .008 
Eotaxin 2.108 (1.270 - 2.947) .012 
FGF basic 1.173 (0.749 - 1.597) .878 
G-CSF 9.870 (6.002 - 13.738) .005 
GM-CSF 1.170 (0.990 - 1.350) .093 
IFN-γ 2.173 (1.686 - 2.661) .005 
IP-10 16.373 (1.678 - 31.068) .005 
MCP-1  1.718 (1.010 - 2.425) .017 
MIP-1α 6.546 (4.121 - 8.971) .009 
MIP-1β 5.351 (3.276 - 7.427) .009 
RANTES 1.112 (0.757 - 1.468) .721 
TNF-α 2.271 (1.844 - 2.698) .005 
VEGF 2.320 (1.594 - 3.046) .009 
Table 4. Plasma and EAT secretory profile of AS patients stratified according to  EAT thickness 
median value 
                       
PLASMA                 
 
               EAT 
 
 Pts below EAT  
median value 
(n = 46) 
_______________ 
pg/ml 
mean±SD 
 
Pts above EAT  
median value 
(n = 46) 
________________ 
pg/ml 
mean±SD 
 
 
 
 
 
P value 
Pts below EAT  
median value 
(n = 46) 
________________ 
pg/ml 
mean±SD 
 
Pts above EAT  
median value 
(n = 46) 
________________ 
pg/ml 
mean±SD 
 
 
 
 
 
P value 
PDGF 2212.1 ±995.7 1107.0±625.1 .010 34.1±1.8 67.0±32.8 .056 
IL-1β 4.8 ±2.2 4.8±1.5 .963 47.8±10.5 84.4±6.3 .000 
IL-1ra 525.1±304.9 447.4±242.3 .541 685.2±137.6 1436.1±163.6 .000 
 IL-2 30.2±41.8 24.2±38.1 .748 17.9±1.6 81.4±6.9 .000 
 IL-4 4.6±1.7 3.5±1.3 .129 2.5±0.9 6.8±1.0 .000 
 IL-5 3.5±1.4 4.2±2.5 .340 1.5±0.5 3.3±1.1 .010 
 IL-6 43.0±34.8 27.6±16.3 .255 52114±28322. 112394.1±18003.4 .004 
 IL-7 17.6±8.1 18.0±17.1 .938 2.7±0.6 5.3±0.8 .000 
 IL-8 61.6±32.6 44.3±14.1 .172 7222.9±3785.8 134151.5±14886.3 .000 
 IL-9 26.4±13.4 28.4±22.9 .792 6.3±1.8 18.0±1.8 .000 
 IL-10 50.3±59.4 35.0±29.4 .503 33.4±3.0 229.8±99.6 .002 
 IL-12 56.3±47.4 41.7±51.6 .504 32.6±8.2 84.1±48.7 .048 
 IL-13 15.2±7.1 11.4±7.9 .246 13.2±3.0 12.7±2.7 .792 
 IL-15 74.8±27.6 132.3±56.3 .093 322.6±54.7 388.4±50.5 .083 
 IL-17 110.5±58.4 128.1±128.6 .655 41.7±15.3 240.7±34.6 .000 
 Eotaxin 119.6±44.9 124.0±97.7 .888 26.0±7.2 177.3±15.6 .000 
FGF basic 95.6±33.1 135.6±103.1 .176 205.7±39.8 389.0±104.7 .006 
 G-CSF 111.3±46.3 131.8±62.6 .382 3548.6±615.5 85329.2±81013.9 .054 
 GM-CSF 119.7±83.5 124.6±130.6 .913 612.5±21.5 620.9±103.6 .864 
 IFN-γ 159.2±80.4 147.6±38.4 .707 134.5±18.4 371.6±42.7 .000 
 IP-10 1635.3±1125.0 1116.5±603.5 .241 179.9±140.5 3809.0±2601.8 .014 
 MCP-1 152.4±55.9 146.0±117.3 .859 3709.8±190.5 18155.8±2274 .000 
 MIP-1α 8.4±6.5 9.8±7.3 .646 30.7±4.3 638.6±122.3 .000 
MIP-1β 226.9±238.4 148.4±58.0 .375 368.3±93.7 1646.2±174.7 .000 
 RANTES 26332±26881 12707.6±10742. 5 .187 233.4±150.7 301.3±98.2 .423 
TNF-α 51.9±23.4 80.8±64.4 .129 63.9±9.6 207.8±17.6 .000 
VEGF 187.6±102.0 64.6±44.4 .004 465.1±198.3 1143.4±805.6 .105 
EAT, Epicardial Adipose Tissue; AS, Aortic Stenosis 
 Table 5. Differences of inflammatory mediators levels in patients taking vs non taking statins in 
plasma and EAT secretome  
 
Plasma P value EAT secretome P value 
PDGF .994 PDGF .056 
IL-1β .366 IL-1β .000 
IL-1ra .962 IL-1ra .000 
IL-2 .251 IL-2 .000 
IL-4 .503 IL-4 .000 
IL-5 .532 IL-5 .010 
IL-6 .021 IL-6 .004 
IL-7 .812 IL-7 .000 
IL-8 .414 IL-8 .000 
IL-9 .723 IL-9 .000 
IL-10 .145 IL-10 .002 
IL-12 .499 IL-12 .048 
IL-13 .721 IL-13 .792 
IL-15 .511 IL-15 .008 
IL-17 .753 IL-17 .000 
Eotaxin .761 Eotaxin .000 
FGF basic .613 FGF basic .006 
G-CSF .583 G-CSF .054 
GM-CSF .930 GM-CSF .0864 
IFN-γ .369 IFN-γ .000 
IP-10 .592 IP-10 .014 
MCP-1  .679 MCP-1 .000 
MIP-1α .011 MIP-1α .000 
MIP-1β .108 MIP-1β .000 
RANTES .631 RANTES .423 
TNF-α .091 TNF-α .000 
VEGF .004 VEGF .105 
 
  
 
Table 6 . Correlation between EAT thickness and EAT inflammatory profile 
 
Epicardial fat 
  Spearman p value 
PDGF .728
*
 .017 
IL-1β .887
**
 .001 
IL-1ra .936
**
 .000 
IL-2 .790
*
 .020 
IL-4 .801
**
 .005 
IL-5 .954
**
 .000 
IL-6 .691
*
 .027 
IL-7 .991
**
 .000 
IL-8 .837
**
 .010 
IL-9 .911
**
 .000 
IL-10 .960
**
 .000 
IL-12 .636
*
 .048 
IL-13 .110 .762 
IL-15 .538 .108 
IL-17 .838
**
 .002 
Eotaxin .850
**
 .007 
FGF basic .917
**
 .000 
G-CSF .813
**
 .004 
GM-CSF .275 .441 
IFN-γ .813
**
 .004 
IP-10 .881
**
 .001 
MCP-1  .711
*
 .048 
MIP-1α .813
**
 .004 
MIP-1β .869
**
 .001 
RANTES .575 .082 
TNF-α .869
**
 .001 
VEGF .569 .086 
 
Figure Legends 
 
Figure 1. Epicardial adipose tissue (EAT) thickness, measured by echocardiography, in patients 
with aortic stenosis (AS) and in control subjects matched for age, gender and body mass index. 
*p<0.001 AS vs Controls. 
 
 
Figure 2. Inflammatory mediators levels in epicardial adipose tissue (EAT) and subcutaneous 
adipose tissue  (SCAT) secretomes in patients with aortic stenosis (AS). 
 
 
